Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
, 59 (6), 401-6

[Comparison of Rifabutin- And Levofloxacin-Based Third-Line Rescue Therapies for Helicobacter Pylori]

[Article in Korean]
Affiliations
Comparative Study

[Comparison of Rifabutin- And Levofloxacin-Based Third-Line Rescue Therapies for Helicobacter Pylori]

[Article in Korean]
Myung Ho Jeong et al. Korean J Gastroenterol.

Abstract

Background/aims: There is increasing need for third-line therapy of Helicobacter pylori due to increasing level of antibiotics resistance. The aim of this study was to compare rifabutin and levofloxacin rescue regimens in patients with first- and second-line Helicobacter pylori eradication failures.

Methods: Patients, in whom a first treatment with proton pump inhibitor-clarithromycin-amoxicillin and a second trial with proton pump inhibitor-bismuth-tetracycline-metronidazole had failed, received treatment with either rifabutin or levofloxacin, plus amoxicillin (1 g twice daily) and standard dose proton pump inhibitor. Eradication rates were confirmed with 13C-urea breath test or rapid urease test 4 weeks after the cessation of therapy.

Results: Eradication rates were 71.4% in the rifabutin group, and 57.1% in the levofloxacin group, respectively. Although there was no significant difference in Helicobacter pylori eradication rates between two groups (p=0.656), rifabutin based regimen showed relatively higher eradication rate.

Conclusions: Helicobacter pylori eradication rates of rifabutin- or levofloxacin-based triple therapy could not achieve enough eradication rate. Further studies would be needed on combination of levofloxacin and rifabutin-based regimen or culture based treatment.

Similar articles

See all similar articles

Cited by 9 PubMed Central articles

See all "Cited by" articles
Feedback